242 related articles for article (PubMed ID: 37357070)
1. Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.
Muhsen IN; Hill LC; Ramos CA
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1107-1124. PubMed ID: 37357070
[TBL] [Abstract][Full Text] [Related]
2. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
3. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
[TBL] [Abstract][Full Text] [Related]
5. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
[TBL] [Abstract][Full Text] [Related]
6. The value of anti-CD30 CAR T cells in Hodgkin lymphoma.
Veyri M
Lancet Haematol; 2024 May; 11(5):e314-e316. PubMed ID: 38555922
[No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy targeting CD30 in Hodgkin lymphoma.
Savoldo B
Clin Adv Hematol Oncol; 2021 Jan; 19(1):24-26. PubMed ID: 33493145
[No Abstract] [Full Text] [Related]
8. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.
Zhang S; Gu C; Huang L; Wu H; Shi J; Zhang Z; Zhou Y; Zhou J; Gao Y; Liu J; Leng Y; Liu X; Zhang Q; Huang L; Tong X; Young KH; Li J; Zhu H; Zhang T
Sci Rep; 2022 Jun; 12(1):10488. PubMed ID: 35729339
[TBL] [Abstract][Full Text] [Related]
9. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G; Fraietta JA; Gerson JN; Van Deerlin VM; Morrissette JJD; Caponetti GC; Paruzzo L; Harris JC; Chong EA; Susanibar Adaniya SP; Svoboda J; Nasta SD; Ugwuanyi OH; Landsburg DJ; Fardella E; Waxman AJ; Chong ER; Patel V; Pajarillo R; Kulikovskaya I; Lieberman DB; Cohen AD; Levine BL; Stadtmauer EA; Frey NV; Vogl DT; Hexner EO; Barta SK; Porter DL; Garfall AL; Schuster SJ; June CH; Ruella M
Nat Med; 2024 Apr; 30(4):984-989. PubMed ID: 38266761
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
11. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
13. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
14. Engineered T Cells: CAR T Cell Therapy and Beyond.
Johnson PC; Abramson JS
Curr Oncol Rep; 2022 Jan; 24(1):23-31. PubMed ID: 35059997
[TBL] [Abstract][Full Text] [Related]
15. Beyond CD19 CAR-T cells in lymphoma.
Leung WK; Ayanambakkam A; Heslop HE; Hill LC
Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
[TBL] [Abstract][Full Text] [Related]
16. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
18. Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.
Bröckelmann PJ; Borchmann S; Borchmann P; Engert A
J Clin Oncol; 2020 Nov; 38(32):3816-3818. PubMed ID: 32946351
[No Abstract] [Full Text] [Related]
19. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
20. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.
Voorhees TJ; Zhao B; Oldan J; Hucks G; Khandani A; Dittus C; Smith J; Morrison JK; Cheng CJ; Ivanova A; Park S; Shea TC; Beaven AW; Dotti G; Serody J; Savoldo B; Grover N
Blood Adv; 2022 Feb; 6(4):1255-1263. PubMed ID: 34666347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
